Company news

AC Immune SA news in 2022

AC Immune SA's news releases, calls and decks from 2022, newest first.

View company

AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

October 27, 2022

AC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome

October 3, 2022

AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer’s Disease

September 25, 2022

AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent

August 31, 2022

AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update

July 27, 2022

AC Immune Announces Upcoming Presentations at the Alzheimer’s Association International Conference

July 21, 2022

AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

June 15, 2022

AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update

April 27, 2022

AC Immune Reports Changes to Senior Management

April 7, 2022

AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update

March 21, 2022

AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference

March 15, 2022

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort

February 14, 2022

AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease

February 3, 2022

Decks in 2022